-
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
03 Oct 2022 12:00 GMT
… positioning the company for its initial public offering. Previously, he served as … University of California, Davis. About Codexis Codexis is a leading enzyme engineering … high performance enzymes and biotherapeutics. Codexis enzymes have applications in the …
-
The Business of their Biology, the Biology of their Business: 10 years after IPOs, how are Amyris, Gevo, Codexis doing?
09 Aug 2022 18:09 GMT
… since the celebrated IPOs of Amyris, Codexis and Gevo showed … s COVID-19 therapeutic. Codexis previously announced the Company … In the second quarter, Codexis had 18 customers who … enabling MAI to utilize Codexis’ evolved terminal deoxynucleotidyl transferase …
-
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs
18 Jun 2021 12:08 GMT
… Binding Orders For Enzyme Products
Codexis, Inc. (NASDAQ: CDXS) … disorders, priced its upsized initial public offering of 15 million shares of … biology workflows, priced its IPO of 6.67 million shares … precision biologics, priced its IPO of 7 million ADSs, …
-
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
16 Jun 2020 20:05 GMT
… company through its successful IPO in 2015, and its … the board. About Codexis, Inc.
Codexis is a leading protein … other proteins as biotherapeutics. Codexis’ proven technology platform delivers … of historical facts regarding Codexis, they are forward-looking …
-
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
28 Feb 2020 12:42 GMT
… )
CNS Pharmaceuticals Inc (NASDAQ: CNSP)
Codexis, Inc. (NASDAQ: CDXS)
Cumberland Pharmaceuticals … : GLYC) (before the market open)
IPO
Passage Bio, a biotech developing …
-
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results And Recent Business Highlights
12 Nov 2024 22:35 GMT
… Chief Technical Officer (CTO) of Codexis Inc., a leading enzyme engineering … .
Completed upsized $179.0 Million initial public offering: In July 2024, Artiva sold … from Artiva's completed initial public offering in July 2024 in which …
-
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
12 Nov 2024 21:05 GMT
… Chief Technical Officer (CTO) of Codexis Inc., a leading enzyme engineering … .
Completed upsized $179.0 Million initial public offering: In July 2024, Artiva sold … proceeds from Artiva’s completed initial public offering in July 2024 in which …
-
Twist Bioscience IPO - Love The Company, Hate The Price
30 Oct 2018 18:08 GMT
… bioconversion using enzymes made by Codexis (CDXS), or it can be … Concern Another concern about the IPO is the Agilent (A) lawsuit … the lawsuit prior to the IPO. The Only Bull Case I …
-
Twist Bioscience Aims For $75 Million IPO
24 Oct 2018 21:37 GMT
… primary valuation metrics: Metric Codexis (CDXS) Twist Bio (TWST … registration statement and IPO Edge) Expected IPO Pricing Date: October … Alpha Marketplace research service IPO Edge includes:
Commentary
… Opinion on the IPO
Members of IPO Edge get the …
-
Homology Medicines Updates Terms For U.S. IPO
22 Mar 2018 11:19 GMT
… (SYN) SOM Innovation Biotech SL Codexis (CDXS) BioMarin Pharmaceutical (BMRN … a successful IPO, the company’s post-IPO market capitalization … ISI and BTIG. Expected IPO Pricing Date: Wednesday, March … U.S. IPOs and members learn the latest IPO research, …